Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb randomized open-label study of risankizumab versus vedolizumab in biologic-naive adults with moderate to severe ulcerative colitis
CTR20253106Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab, vedolizumab in autoimmune colitis, sponsored by AbbVie Inc.. Started Nov 2025; status: active.
02
Drugs
risankizumabvedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20253106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253106.